USPTO serial 79312182
ELATIVE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 29, 2022
- Examiner
- HUDSON, TAMARA BREE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ELATIVE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brooks R. Bruneau
Brooks R. Bruneau FisherBroyles LLP100 Overlook CenterSecond FloorPrinceton, NJ 08540Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; organic preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; diagnostic preparations for medical use; diagnostic reagents for medical use | ACTIVE | — |
| 042 | Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for pharmaceutical products for others, in particular conducting clinical trials for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely, providing information, results and data relating to scientific or medical research and development of pharmaceutical products, via an online searchable database; conducting clinical trials for others; pharmaceutical and biological product development and research services for third parties; conducting clinical research for others; evaluation of the efficacy of pharmaceutical products; clinical product development services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 19, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 12, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 23, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 23, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 29, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 8, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 29, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 11, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 11, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 10, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 22, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 22, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 22, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 9, 2021 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 9, 2021 | ALIE | ASSIGNED TO LIE | — |
| Dec 8, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 6, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 6, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 6, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 11, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 25, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 25, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 7, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 6, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 3, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 12, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 8, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 7, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jun 3, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |